Everything aside at a minimum the US needs more transparency about pricing. The whole system with its coupons, rebates and middlemen seems to be set up to hide the real cost of drugs. Without transparency no real discussion can be had.
Because I have an iPhone. It's made executives and shareholders at Apple quite rich. It's also, I'm confident, advanced the state-of-the-art far faster than if Apple had been a government-regulated utility of sorts, limited to a "fair" 10% profit margin.
If people were talking about the government exercising monopsony power to drive down the price of iPhones, I'd (a) except Apple to protest vigorously; and (b) worry about the impact on smartphone innovation. Drugs are no different. The fact that drugs are important to society doesn't change the basic mechanics of a capital- and talent-intensive industry.
In this context the "luxury treatments" are drugs under patent and the "cheap options for all" are generics.
And then we can identify a specific problem -- we don't have enough generics because unless a drug is under patent, nobody has the incentive to pay to put it through FDA trials.
But you can't solve that by removing the profit from the "luxury drugs" -- that only makes it worse. Then nobody has the incentive to pay for FDA trials for anything.
The actual problem is that FDA trials are an unfunded mandate. Either they need to be made significantly less expensive somehow or the government needs to fund them itself so that more unpatented generics can actually get approved.
https://www.jhsph.edu/news/news-releases/2018/cost-of-clinic... https://www.outsourcing-pharma.com/Article/2018/09/26/Clinic...
The trial costs are small compared to R&D costs, but that's only because R&D costs are very large. So it's millions of dollars compared to billions of dollars.
But generics don't have R&D costs, they already exist and are out of patent. Which correspondingly makes them much less profitable -- that's the whole point -- and then "millions of dollars" becomes a significant cost.
Moreover, it's a free rider problem, because once you pay for it for a generic drug, anyone can make it, but they didn't have to pay the millions of dollars for the trials so now they can undercut your price.
As a result everybody sits around waiting for somebody else to spend several million dollars for a trial instead of doing it themselves, which means that nobody does it.
https://docs.house.gov/meetings/GO/GO00/20190129/108817/HHRG...
Yes, drug companies don't want drugs to become a commodity. Nobody wants their products to become commodities. And we have to acknowledge that, at least maybe, the public shouldn't want drugs to become commodities (at least, not during the period of patent protection). Companies in commodity markets don't innovate. Look at where innovation is happening in the PC market. It's happening in companies that can make a big profit (Google, Apple), not companies that deal in commodities (Acer, HP).
But put that aside. Maybe the best thing is for drug companies to be like Acer rather than Apple. At the very least, honest reporting should acknowledge that we're talking about trade-offs. In the last few decades, new drugs and medical devices have revolutionized treatment for things like HIV, breast cancer, leukemia, Hepatitis C, prostate cancer, etc. The 5-year survival rate for prostate cancer has gone up from 68% in the 1970s, to 99% today. HIV went from being a death sentence to a chronic condition. Many leukemias went from being death sentences to being extremely treatable. That progress wouldn't be possible without the tens of billions of dollars a year that drug companies invest in R&D. We can choose to slow down that pace, in exchange for making the existing treatments more widely accessible. That's a totally acceptable choice. But it's deception to make it seem like it's not a choice.